Effector Therapeutics Stock Performance
| EFTR Stock | USD 0.0002 0.00 0.00% |
Effector Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 5.91, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Effector Therapeutics will likely underperform. Use Effector Therapeutics mean deviation, jensen alpha, as well as the relationship between the Jensen Alpha and day median price , to analyze future returns on Effector Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Effector Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Effector Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 8.7 M | |
| Total Cashflows From Investing Activities | 14.5 M | |
| Free Cash Flow | -29.6 M |
Effector Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.02 in Effector Therapeutics on October 31, 2025 and sell it today you would earn a total of 0.00 from holding Effector Therapeutics or generate 0.0% return on investment over 90 days. Effector Therapeutics is currently generating 4.2328% in daily expected returns and assumes 37.6229% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Effector, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Effector Therapeutics Target Price Odds to finish over Current Price
The tendency of Effector Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0002 | 90 days | 0.0002 | about 69.47 |
Based on a normal probability distribution, the odds of Effector Therapeutics to move above the current price in 90 days from now is about 69.47 (This Effector Therapeutics probability density function shows the probability of Effector Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 5.91 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Effector Therapeutics will likely underperform. In addition to that Effector Therapeutics has an alpha of 3.9196, implying that it can generate a 3.92 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Effector Therapeutics Price Density |
| Price |
Predictive Modules for Effector Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Effector Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Effector Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Effector Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Effector Therapeutics is not an exception. The market had few large corrections towards the Effector Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Effector Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Effector Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 3.92 | |
β | Beta against Dow Jones | 5.91 | |
σ | Overall volatility | 0.0002 | |
Ir | Information ratio | 0.11 |
Effector Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Effector Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Effector Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Effector Therapeutics is way too risky over 90 days horizon | |
| Effector Therapeutics has some characteristics of a very speculative penny stock | |
| Effector Therapeutics appears to be risky and price may revert if volatility continues | |
| Effector Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (35.81 M) with loss before overhead, payroll, taxes, and interest of (21.62 M). | |
| Effector Therapeutics currently holds about 41.04 M in cash with (29.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Effector Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Effector Stock often depends not only on the future outlook of the current and potential Effector Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Effector Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.2 M | |
| Cash And Short Term Investments | 18.4 M |
Effector Therapeutics Fundamentals Growth
Effector Stock prices reflect investors' perceptions of the future prospects and financial health of Effector Therapeutics, and Effector Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Effector Stock performance.
| Return On Equity | -9.47 | |||
| Return On Asset | -0.83 | |||
| Current Valuation | (5.13 M) | |||
| Shares Outstanding | 4.7 M | |||
| Price To Earning | 1.03 X | |||
| Price To Book | 0 X | |||
| Price To Sales | 69.65 X | |||
| EBITDA | (32.78 M) | |||
| Cash And Equivalents | 41.04 M | |||
| Cash Per Share | 0.99 X | |||
| Total Debt | 20.55 M | |||
| Debt To Equity | 1.03 % | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (29.55 M) | |||
| Earnings Per Share | (12.57) X | |||
| Total Asset | 20.54 M | |||
| Retained Earnings | (179.38 M) | |||
About Effector Therapeutics Performance
Assessing Effector Therapeutics' fundamental ratios provides investors with valuable insights into Effector Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Effector Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California. Effector Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.Things to note about Effector Therapeutics performance evaluation
Checking the ongoing alerts about Effector Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Effector Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Effector Therapeutics is way too risky over 90 days horizon | |
| Effector Therapeutics has some characteristics of a very speculative penny stock | |
| Effector Therapeutics appears to be risky and price may revert if volatility continues | |
| Effector Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (35.81 M) with loss before overhead, payroll, taxes, and interest of (21.62 M). | |
| Effector Therapeutics currently holds about 41.04 M in cash with (29.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Effector Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Effector Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Effector Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Effector Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Effector Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Effector Therapeutics' stock. These opinions can provide insight into Effector Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Effector Stock Analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.